The UK and US have reached a major trade agreement that will preserve no duties on UK medicine products entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to raise spending on pharmaceuticals through the NHS. This pledge guarantees that import taxes on these key exports will stay at zero for a timeframe of three years.
This deal follows earlier statements to dramatically increase tariffs on branded pharmaceutical products, with potential rates discussed up to one hundred percent.
"This deal with the Britain bolsters the global environment for new treatments and brings much-needed fairness to transatlantic drug exports," a release noted.
Trade Importance
Pharmaceuticals constitute one of the UK's most significant exports to the United States, which is clearly the largest destination for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months leading up to the third quarter, the UK exported drugs worth £11.1bn to the US. This value accounted for 17.4% of total UK exports in that span.
"This agreement secures work, stimulates investment and sets the stage for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary remarked.
Key NHS Changes
The pact entails several specific pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The sum manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Last year, rebates were more than 20%.
Broader Context
The deal follows a ongoing row between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were heightened by arguments that US consumers were charged significantly more for the same drugs than people in the UK and Europe.
In recent months, several major drug company projects in the UK have been paused or abandoned, while substantial expansions have been pledged toward American operations.
One official stated that the NHS must spend more on medicines, noting that its expenditure on drugs had shrunk as a share of its total funding over the previous ten-year period.
